相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
K. -L. Garm Spindler et al.
ANNALS OF ONCOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
Rene Adam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM
J. A. Wickenden et al.
ONCOGENE (2008)
Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf
Greg Buhrman et al.
STRUCTURE (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
A Conlin et al.
GUT (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
